The FDA last week cleared Genentech’s Actemra for the treatment of systemic sclerosis, a rare autoimmune disease occurring in patients with interstitial lung disease. The drug is the first biologic approved for this condition, and will be Actemra’s sixth FDA-granted indication overall. For the treatment of rheumatoid arthritis, Actemra currently holds preferred status for 21% of all covered lives under the pharmacy benefit, with utilization management restrictions applied in most cases. The biologic is classified as a specialty drug for 14% of covered lives.
SOURCE: MMIT Analytics, as of 3/8/21